emerging markets

Procter & Gamble and Colgate-Palmolive emerge as premier long-term consumer staples plays, leveraging unmatched brand moats and emerging market dominance for sustained growth.

Jumia stock surged 17.56% after Q1 results showed 24% customer growth, 39% revenue increase to $50.6M, and 26% operating loss reduction. Company reaffirmed 2027 profitability target.

VXUS offers broad international diversification across 8,800 stocks with a 0.05% expense ratio. International equities trade at 17x earnings versus 25x for U.S. stocks.

Kaspi.kz's dominant Kazakhstan platform trades at depressed 6x forward earnings amid concerns over Turkey expansion, governance, and accounting quality.

Novonesis reports 7% Q1 organic growth and 37.8% EBITDA margin, confirms full-year guidance, and secures EUR 1.7B in bond financing plus Thailand facility acquisition.

Novonesis reported 7% Q1 organic sales growth, 37.8% EBITDA margins, and secured €1.7B funding while acquiring a Thai production facility for expansion.

Nu Holdings stock up 196% in three years with 50% annualized revenue growth, but Latin American economic volatility poses significant investment risk.

SPEM emerging-markets ETF posts 9% YTD gains across 3,000 holdings, outperforming U.S. indexes as investors diversify from overvalued large-caps.

China's massive trade surplus bolsters Hong Kong equities despite Western investor retreat, reflecting a generational shift away from China exposure.

Coca-Cola reports 10% Q1 organic growth, robust $2B cash flow, and trades below historical P/E. All 15 analysts rate Buy with $90 target.

Hobbs Wealth Management purchases $7.3M stake in BlackRock's CORO ETF, signaling renewed institutional appetite for international country rotation strategies.

U.S. investors should allocate 5% to international markets via ETFs like $VXUS to diversify from Magnificent Seven concentration amid valuation concerns and geopolitical risks.

Global money transfer app market to surge from $22.5B in 2024 to $52B by 2030, driven by remittances and digital adoption. China growing fastest at 20.1% CAGR.

$SCHE outperforms $NZAC with 0.07% fees, 2.7% yield versus 0.12% fees, 1.8% yield, offering pure emerging markets exposure over ESG-screened global alternatives.

International stocks surge as VXUS gains 9% year-to-date, outpacing S&P 500's 3%. Strategists expect international equities to lead over the next decade.

Nasdaq-100 gained 17.4% since March 30 despite Iran war concerns as tech investors shake off geopolitical fears and embrace broader market recovery.

VXUS offers 8,700+ holdings at 0.05% fees; IXUS provides 3.18% yield at 0.07% cost. Both delivered 38% one-year returns, making either viable for global diversification.

Retirement Guys Formula acquires $3.72M stake in JPMorgan International Value ETF, signaling renewed confidence in overseas equities after strong outperformance.

Global vulvar cancer market expected to expand through 2035, driven by aging populations and HPV prevalence. Merck, Bristol Myers Squibb, and AstraZeneca lead innovation in immunotherapies despite reimbursement headwinds.

VXUS offers broader diversification with lower costs and superior long-term returns, while EEM's emerging market focus delivered stronger recent gains but higher volatility.